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ABSTRACT
Tumor relapse after therapy typifies hepatocellular carcinoma (HCC) and is 
believed to be attributable to residual cancer stem cells (CSCs) that survive treatment. 
We have previously identified a CSC population derived from HCC that is characterized 
by CD133. Despite our growing knowledge of the importance of this subset of cells in 
driving HCC, the regulatory mechanism of CD133 is not known. Epigenetic changes 
are believed to be essential in the control of cancer and stem cells. Here, we report 
the epigenetic regulation of CD133 by miR-142-3p. The interaction between CD133 
and miR-142-3p was identified by in silico prediction and substantiated by luciferase 
reporter analysis. Expression of CD133 was found to be inversely correlated with 
miR-142-3p in HCC clinical samples as well as in cell lines. Importantly, lower miR-
142-3p expression in HCC was significantly associated with worst survival. Functional 
studies with miR-142-3p stably transduced in HCC cells demonstrated a diminished 
ability to self-renew, initiate tumor growth, invade, migrate, induce angiogenesis 
and resist chemotherapy. Rescue experiments whereby CD133 and miR-142-3p is 
simultaneously overexpressed compensated the deregulated ability of the cells to 
confer these features. Thus, miR-142-3p directly targets CD133 to regulate its ability 
to confer cancer and stem cell-like features in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
commonly diagnosed malignancy of the liver and ranks 
the fifth most frequently diagnosed cancer in the world. 
The overall prognosis of HCC is dismal due to the high 
rate of recurrence and the chemotherapy resistant nature 
of the tumor. Recently, the cancer stem cell (CSC) 
model has helped explain why tumor eradication has not 
been achieved despite advances in treatment. The CSC 
hypothesis posits that malignant growth arises from a 
rare subset of cells within a tumor that provide it with 
unlimited self-renewal and tumorigenic capacity. We and 
others have previously identified a specific subset of liver 
CSCs that is marked by their CD133 surface phenotype. 
CD133+ liver CSCs bear features that include the abilities 
to self-renew, differentiate, resist standard chemotherapy 
and initiate tumors at limited dilution [1-3]. CD133 is not 
just a marker of liver CSCs. It was also found to play an 
important functional role in regulating liver tumorigensis 
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as evident by CD133 shRNA knockdown experiments 
[4]. Clinically, CD133 expression was also found to have 
prognostic value in HCC as its presence was associated 
with worse overall survival and higher recurrence rates. 
Importantly, our results are consistent with studies by other 
groups where liver CSCs are also found to be marked by 
CD133 and that CD133 expression is an important risk 
factor for overall survival in HCC, further demonstrating 
the prominence of CD133 in the cancer [5-9]. Findings 
by us and others now clearly suggest the importance of a 
CD133 liver CSC subset in driving HCC. However, the 
underlying molecular mechanism by which CD133 is 
regulated is still not clear. 
Epigenetic changes, including miRNA regulation, 
promoter methylation and histone modification, are 
believed to be integral to the behavior of CSCs and their 
progeny [10]. In particular, there has been increasing 
evidence in support of a role of miRNA in the regulation 
of cancer stem cell-like properties in CSCs in recent years 
[11-12]. Specifically in HCC, although there is increasing 
work in the study of deregulated miRNAs in various liver 
CSC subsets as compared with non-CSC differentiated 
counterparts, for example miR-181 in EpCAM+ liver 
CSCs [13], miR-150 up-regulation in CD133+ liver CSCs 
[14] and our previous work on miR-130b and TP53INP1 
interaction in CD133+ liver CSCs [3], the role of miRNAs 
in the direct regulation of CD133 in HCC has not been 
explored.
Here, we report the epigenetic regulation of the 
functional liver CSC marker CD133 by miR-142-3p. 
By in silico prediction analysis, we found the 3’UTR of 
CD133 to encompass a putative binding region bearing 
significant complementarity against miR-142-3p. The 
bona fide interaction between CD133 and miR-142-3p 
was validated by luciferase reporter assays. Expression of 
CD133 was found to be inversely correlated with miR-
142-3p in a panel of liver cell lines with different CD133 
expression levels. Likewise, expression of miR-142-3p 
was also significantly repressed in HCC clinical samples, 
as compared with adjacent non-tumor liver tissues. This 
is inversely correlated with CD133 expression in HCC 
where we previously reported CD133 to be preferentially 
expressed in HCC, but is detected at only low or absent 
levels in non-tumor liver tissues [1, 3]. Lower miR-142-
3p expression in HCC was significantly associated with 
worst disease free survival. miR-142-3p was also found 
to be preferentially expressed in the CD133- subset 
isolated from HCC cells PLC8024, Huh7 and SNU182 
as compared to its CD133+ counterpart. In addition, we 
also observed an inverse CD133 pattern, at both genomic 
and proteomic levels, following lentiviral up-regulation 
of miR-142-3p in CD133-expressing Huh7 and PLC8024 
HCC cells. Functional studies in Huh7 and PLC8024 with 
miR-142-3p stably transduced demonstrated a diminished 
ability to self-renew, initiate tumor growth, invade, 
migrate, induce capillary tube formation in endothelial 
cells and resist standard chemotherapy (cisplatin and 
5-fluorouracil). Rescue experiments whereby CD133 is 
overexpressed in Huh7 with miR-142-3p already stably 
transduced compensated the deregulated ability of the 
cells to confer the above stated cancer and stem cell-like 
features. Taken together, our results show that miR-142-
3p plays a critical role in the control of the downstream 
functional CSC target CD133 in HCC.
RESULTS
CD133 is a direct target of miR-142-3p
By flow cytometry and immunohistochemistry 
analyses on both freshly resected and paraffin embedded 
clinical tissue samples, we [1, 3] and others [6] have 
previously reported that the liver CSC marker CD133 
is represented only in a small subset of the tumor 
population (~0.5 – 25%) in human HCC specimens. Its 
expression had prognostic value in HCC as its presence 
was associated with worse overall survival and higher 
recurrence rates [3]. In contrast, CD133 expression in 
normal hepatocytes, biliary epithelial structures in portal 
area or non-tumor liver tissues adjacent to HCC was 
significantly lower, if not, completely absent at times 
[3, 6]. Despite the importance of CD133 in cancer and 
stem cell biology, limited is known about the regulation 
of CD133 expression in HCC. Recent studies have 
implicated miRNAs as prominent factors that contribute 
to the phenotype of cancer stem cells [10]. Here, we 
hypothesized whether epigenetic miRNA regulation 
would also play a role in regulating CD133 in HCC. 
In an effort to identify human miRNAs that potentially 
regulate CD133, in silico prediction softwares TargetScan 
and miRanda were used to screen for common candidate 
miRNAs that bind to the 3’UTR of CD133. Using this 
method, only one conserved miRNA (miR-142-3p) 
was found to have predicted consequential pairing with 
the 3’UTR of CD133 with a 8mer seed match. Based-
pairing complementation found the 3’UTR of CD133 to 
encompass a putative binding region (position 287-294) 
bearing significant 8mer complementarity against miR-
142-3p (Figure 1A). This 3’UTR element of CD133 and 
miR-142-3p are extremely conserved among different 
species, as shown by their identical sequences in 
chimpanzee, monkey, mouse, rat, guinea pig, rabbit and 
human orthologs, suggesting a functional role (Figure 
1B). To validate whether CD133 is a bona fide target of 
miR-142-3p, a full-length human CD133 3’UTR fragment 
was cloned downstream of the firefly luciferase reporter 
gene. Compared with miR-control experiments, luciferase 
activity was markedly reduced by approximately 30% 
in the cells co-transfected with miR-142-3p and CD133 
3’UTR in the sense direction. As a reflection of specificity, 
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this inhibitory effect was abolished when anti-sense 
3’UTR CD133 was used in place of the sense construct 
(Figure 1C). 
Interestingly, the expression of CD133 was also 
found to be inversely correlated with miR-142-3p in 
a series of liver cell lines expressing different CD133 
expression levels. Liver cell lines with absent or low 
CD133 expression had relatively higher levels of miR-
142-3p (MiHA, BEL7402, QSG-7701, QGY-7703 
and HepG2), while, in contrast, liver cell lines with 
high CD133 levels expressed relatively lower levels 
of miR-142-3p (PLC8024, Huh7 and Hep3B) (Figure 
1D). Glycosylated CD133 at the proteomic level was 
further analyzed by flow cytometry, where its expression 
was found to closely match with its genomic level as 
detected by qPCR (Figure 1E), suggesting the inverse 
correlation extends to the proteomic level. In addition, 
we also observed an inverse CD133 pattern, at both 
genomic and proteomic levels, following lentiviral up-
regulation of miR-142-3p in CD133-expressing Huh7 
and PLC8024 HCC cells, as compared to empty vector 
(EV) controls (Figure 1F). miR-142-3p was also found 
to be preferentially expressed in the CD133- subset 
isolated from HCC cells PLC8024, SNU182 and Huh7 as 
compared to its CD133+ counterpart (Figure 1G).
Figure 1: Regulation of CD133 by miR-142-3p. (A) In silico prediction identified CD133 to be a target of miR-142-3p. (B) The 
chimpanzee (ptr: pan troglodytes), monkey (mml: macaca mulatta), bushbaby (oga; otolemur garnetti), treeshrew (tbe: tupaia belangeri), 
mouse (mmu: mus musculus), rat (rno: rattus norvegicus), guinea pig (cpo: cavia porcellus), rabbit (ocu: oryctolagus cuniculus) and 
human (hsa: homo sapiens) miR-142-3p and the predicted binding site in the 3’UTR of CD133 in different species were checked for 
alignment. The positions of the miRNA binding sites corresponded to the location of the GenBank sequence NM_006017. (C) Validation 
of miR-142-3p binding to the 3’UTR of CD133 by lucifearse reporter assay. Full length 3’UTR of CD133 (full-length) was PCR amplified 
and then cloned downstream of a firefly luciferase gene. Specificity of the inhibition was determined using anti-sense constructs (3’ to 5’ 
orientation). The pRL-TK Renilla luciferase plasmid was co-transfected as a normalization control for firefly luciferase activity. (D) The 
inverse correlations of CD133 (red line) and miR-142-3p (blue line) expression were determined across a panel of liver cell lines by qPCR. 
HepG2 was used as the calibrator. (E) Flow cytometry analysis of glycosylated protein CD133 expression in the same panel of liver cell 
lines. (F) Left panel: Stable overexpression of miR-142-3p in HCC cells PLC8024 and Huh7 by lentiviral transduction was confirmed by 
qPCR analysis. Middle and right panels: qPCR and Western blot analyses of CD133 expression following stable transduction of miR-142-
3p or empty vector (EV) control in HCC cell lines PLC8024 and Huh7. (G) qPCR analysis for miR-142-3p expression in sorted CD133+ 
and CD133- subsets isolated from HCC cells PLC8024, SNU182 and Huh7.
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miR-142-3p is frequently under-expressed in HCC 
and lower expression is significantly associated 
with worst overall survival
To determine whether miR-142-3p expression is 
clinically relevant in HCC, we then extended our studies 
to the use of clinical tissue specimens. Expression of 
miR-142-3p was significantly repressed in HCC clinical 
samples, as compared with adjacent non-tumor liver 
tissues (n = 43; p < 0.001; Figure 2A). Compared by 
log-rank test analysis, patients with low miR-142-3p 
expression in HCC displayed worse overall disease-
free survival (estimated mean = 32.349 months) when 
compared to those patients with high miR-142-3p 
expression (estimated mean = 52.824 months) (p = 
0.049; Figure 2B). miR-142-3p expression was not found 
to correlate with another clinicopathological feature 
(Supplementary Table 1); but is inversely correlated with 
CD133 expression in HCC where we and others have 
previously reported CD133 to be preferentially expressed 
in HCC, but is detected at only low or absent levels in 
non-tumor liver tissues [3].
miR-142-3p overexpression inhibits the ability of 
CD133-expressing HCC cells to self-renew, initiate 
tumors, invade, migrate and resist chemotherapy
Since CD133 is a known functional liver CSC 
marker [4], we next examined whether miR-142-3p 
overexpression has any effect on inhibition of cancer 
and stem cell-like properties. Stable transduction with 
a lentiviral vector containing the primary transcripts 
of miR-142-3p produced high levels of mature miR-
142-3p in Huh7 and PLC8024 HCC cells (Figure 1F). 
miR-142-3p transduced Huh7 and PLC8024 HCC 
cells showed diminished proliferation compared with 
control cells transduced with empty vector (EV) alone, 
as measured by XTT cell proliferation assay (Figure 
3A). We also examined the effect of increased miR-
142-3p expression on self-renewal and tumor growth. 
HCC cells with miR-142-3p overexpressed formed 
smaller and less spheroids than cells transduced with 
empty vector controls in a significantly shorter period of 
time (Figure 3B). Importantly, miR-142-3p transduced 
spheroids could not be passaged from one generation 
to another, whereas the untransduced spheres could, 
demonstrating their diminished self-renewal ability in 
vitro. Further, stable overexpression of miR-142-3p also 
led to a significant decrease in the ability of HCC cells 
to migrate and invade through an extracellular matrix 
coating (Figure 3B). Human umbilical vein endothelial 
cells (HUVEC) treated with conditioned media collected 
from miR-142-3p overexpressed showed a diminished 
ability to induce capillary tube formation as compared 
with medium collected from control cells (Figure 3B). 
When implanted into the flanks of immunodeficient 
mice, the growth of HCC cells with miR-142-3p 
overexpressed was significantly diminished. Of the 5 mice 
per group in Huh7 and PLC8024, empty vector control 
cells gave rise to tumors in 4 animals at approximately 
5 weeks post-injection, while none of the animals 
injected with miR-142-3p overexpressing cells could 
form tumors (Figure 3C). In addition, HCC cells with 
miR-142-3p overexpressed were also more sensitive to 
chemotherapeutic reagents cisplatin and 5-fluorouracil, as 
evident by the significant increase in apoptotic / necrotic 
cells. Cisplatin and 5-fluorouracil-induced apoptosis in 
Huh7 HCC cells increased from 23.9% to 44.3% and 
17.7% to 29.9%, respectively (Figure 4A top). Similar 
observations were likewise observed in another HCC cell 
line model PLC8024 (cisplatin – from 25.8% to 38.6% and 
5-fluouracil – from 36.4% to 49.2%) (Figure 4A bottom).
Figure 2: miR-142-3p is frequently down-regulated in HCC. (A) miR-142-3p expression in matched non-tumor (NT) and HCC 
(n = 43) as determined by qPCR. The boxes contain the values between the 25th and 75th percentiles, the lines across the boxes indicate the 
median, and the whiskers extend to the highest values excluding outliers and extremes. (B) Correlation of miR-142-3p expression with 
HCC patient’s cumulative disease-free survival rates, as determined by log-rank test.
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Figure 3: miR-142-3p regulates cancer stem cell-like properties in HCC. (A) Growth curve of Huh7 and PLC8024 cells 
stably transduced with empty vector (EV) control or miR-142-3p, as determined by XTT cell proliferation assay. (B) Representative 
images of spheroid formation, migration, invasion and capillary tube formation assays in Huh7 and PLC8024 cells with miR-142-3p stably 
overexpressed as compared with their controls. (C) Representative image of the tumors formed in nude mice following injection of control 
cells (left flank) and miR-142-3p overexpressing (right flank) Huh7 and PLC8024 cells. Magnification at 400x. 
Figure 4: miR-142-3p overexpressing HCC cells exhibit a decreased ability to resist standard chemotherapy. (A) 
AnnexinV-APC and 7-ADD flow cytometry analysis was performed to determine the extent of apoptosis in Huh7 and PLC8024 cells, with 
or without miR-142-3p overexpressed, following incubation with chemotherapeutic drugs cisplatin or 5-fluorouracil. Red box depicts both 
apoptotic and necrotic cells.
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miR-142-3p regulates cancer stem cell-like 
properties in HCC via the direct targeting of 
CD133
To address whether the above observed phenotype is 
indeed due to the suppression of CD133 and not from the 
targeting of other cellular genes by miR-142-3p, a rescue 
experiment was performed. We co-transduced Huh7 HCC 
cells with miR-142-3p and CD133 or with miR-142-3p 
and vector control. Stable CD133 overexpression was 
confirmed at genomic and proteomic levels by qPCR and 
Western blot (Figure 5A-B). Indeed, Huh7 cells that have 
dual stable overexpression of miR-142-3p and CD133 had 
a compensated ability to proliferate, self-renew, migrate, 
invade and induce capillary tube formation in HUVECs 
(Figure 5C-D), as compared to Huh7 cells with miR-142-
3p and vector control overexpressed. 
DISCUSSION
The CD133 epitope has now been identified as 
a tumor marker in a variety of cancer types for the 
purification of a specific subset of cells that demonstrate 
cancer stem cell phenotype. CD133 cancer stem cell 
subpopulations have been found in glioblastoma, 
colorectal cancer, lung cancer, head and neck cancer and 
hepatocellular carcinoma. Expression of CD133 has not 
only been linked to a more aggressive cellular behavior, 
it also been extensively correlated with advanced disease 
stage and worst overall survival. Our group has a long-
standing interest in CD133 liver CSC research. We have 
previously identified a group of CSCs from HCC that is 
marked by their CD133 surface phenotype and bearing 
unique features that include the ability to self-renew, 
differentiate, initiate tumors in vivo and resist standard 
chemotherapy [1-3]. Further to its role as a liver CSC 
marker, CD133 also plays a functional role in regulating 
tumorigenesis of liver CSCs as evident via CD133 
shRNA knockdown experiments [4]. CD133 represented 
only a minority of the tumor population in human HCC 
specimens (range ~1 to 25% by flow cytometry). Its 
expression had prognostic value in HCC as its presence 
was associated with advanced tumor stage as well as 
worse overall survival and higher recurrence rates [3]. In 
contrast, CD133 expression in their corresponding non-
tumor liver tissues was significantly lower, if not at times 
almost absent [1, 3]. Recently, we also furthered our work 
to delineate the molecular mechanism by which CD133+ 
liver CSCs drive HCC, and found CD133 to confer 
resistance to standard chemotherapy through an activated 
Akt and Bcl-2 survival pathway [2]; and to promote 
Figure 5: miR-142-3p regulates cancer stem cell-like properties in HCC via the direct targeting of CD133. (A-B) 
Stable overexpression of CD133 in Huh7 cells with miR-142-3p stably overexpressed was confirmed at both genomic and proteomic 
levels by qPCR and Western blot, respectively. M68 stands for pReceiver-M68 negative control vector in which CD133 was cloned into. 
(C) Growth curve of miR-142-3p overexpressing Huh7 cells stably transfected with M68 control vector and CD133, as determined by 
XTT cell proliferation assay. (D) Representative images of spheroid formation, migration, invasion and capillary tube formation assays 
demonstrating the ability of CD133 overexpression in miR-142-3p expressing Huh7 to rescue cancer and stem cell-like properties in HCC. 
Magnification at 400x.
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angiogenesis through a deregulated neurotensin / IL-8 
signaling pathway [4]. In addition, we also found HCC 
cells marked by the CD133+CD24+ phenotype to distinctly 
represent a metastatic liver CSC subset [15]. Importantly, 
our results are consistent with past studies by other groups 
where liver CSCs from HCC cell lines are also found to 
be marked by CD133 [5-8] and that CD133 expression is 
an important risk factor for overall survival in HCC [9], 
thus further demonstrating the prominence of CD133 in 
the cancer. These results suggest that CD133 liver CSCs 
represent an important subset of cells for HCC formation 
and recurrence. Two recent reports have shown elevated 
expression of CD133 in HCC to be associated with line-1 
demethylation [16] and to be controlled by TGFβ1 [17]. 
Despite our growing understanding of this subset of cells, 
the mechanism by which CD133 in HCC is regulated 
remains limited. Critical to our understanding of CD133 
liver cancer stem cells at a broader perspective, the present 
study is, to our knowledge, the first to identify miRNA 
epigenetic regulation on the control of CD133 expression 
and function in HCC. Analysis by in silico prediction and 
luciferase reporter assays identified miR-142-3p to play 
a critical role in the targeting of CD133. Expression of 
CD133 and miR-142-3p were inversely correlated in 
liver cell lines and HCC clinical samples. An inverse 
pattern of the two was also observed following lentiviral 
overexpression of miR-142-3p in CD133 expressing HCC 
cells Huh7 and PLC8024. Functional studies in vitro and 
in vivo found miR-142-3p to regulate the ability of HCC 
cells to confer cancer and stem cell-like properties, via 
the direct targeting of CD133. miR-142-3p has previously 
been implicated to control migration and invasion in HCC 
through negatively regulating RAC1 [18]. Further, shortly 
prior to the submission of this article, a study by Shen et 
al. found miR-142-3p to function as a tumor suppressor 
in colon cancer cells by targeting CD133, ABCG2 and 
LGR5 [19], though no rescue functional experiments were 
performed to delineate which of the three cellular targets 
was most crucial in mediating the effects of miR-142-3p 
in colon cancer cells. To address whether the deregulated 
cancer and stem cell-like phenotype is indeed due to the 
suppression of CD133 and not from the targeting of other 
cellular genes by miR-142-3p, rescue experiments were 
performed in our present study. In summary, our results 
show that the expression and function of the liver CSC 
marker CD133 is epigenetically regulated by miR-142-
3p in HCC. Clinically, lower expression of miR-142-3p 
in HCC is significantly correlated with a worst overall 
survival, thus suggesting that miR-142-3p could possibly 
represent a good prognostic marker for the disease. 
Lastly, we would also like to discuss an alternative 
point of view on therapeutic failures and the concept 
of “cancer stemloids” as introduced by Dr. Mikhail 
Blagosklonny [22, 23]. There is now solid data to show 
that cancer cells with stem cell-like properties represent 
a critical root of tumor growth. However, whether 
active proliferation is a defining functional property of 
this subset of cancer cells remains controversial [24]. 
Recently, it has been suggested that the selective killing 
of cancer stemloids (cancer cells with both stem cell-
like and proliferating properties), possibly by cycle-
dependent therapy, should be targeted for more efficient 
eradication of cancer. Regardless of the terminology used, 
we believe that successful irradiation of tumor growth 
would be best achieved through the use of a combination 
of therapy that targets both actively proliferating cancer 
cells as well as cancer cells with stem cell-like features 
and possibly together with drugs that target the tumor 
microenvironment. 
MATERIALS AND METHODS
Cell culture
HepG2, Hep3B and SNU182 were obtained from 
the American Type Culture Collection (Manassas, VA). 
QSG-7701, QGY-7703, BEL7402 and PLC8024 were 
obtained from the Institute of Virology, Chinese Academy 
of Medical Sciences, Beijing, China. MiHA was provided 
by Dr. J.R. Chowdhury, Albert Einstein College of 
Medicine, New York [20]. Huh7 was provided by Dr. H. 
Nakabayashi, Hokkaido University School of Medicine, 
Japan [21]. All cell lines, except HepG2, were cultured in 
DMEM medium (Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (Invitrogen), penicillin 
(500 U/ml) and streptomycin (500 µg/ml) in a 5% CO
2
 
incubator at 37oC. HepG2 was maintained in EMEM 
medium (ATCC, Manassas, VA) supplemented with same 
concentration of FBS and penicillin and streptomycin. All 
cell lines used in this study were regularly authenticated 
by morphological observation and tested for absence of 
Mycoplasma contamination using MycoAlert kit (Lonza, 
Switzerland).
Collection of non-tumor and HCC tissue clinical 
samples
A total of 43 matched HCC and adjacent non-
tumor clinical samples were collected from the Sun 
Yat-Sen University Cancer Centre (Guangzhou, China). 
All samples used in this study were approved by the 
committee for ethical review of research involving human 
subjects at the Sun Yat-Sen University.
RNA isolation, cDNA synthesis, RT-PCR and 
quantitative real-time PCR (qPCR)
Total RNA was isolated by Trizol reagent 
(Invitrogen). cDNA was synthesized using the 
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PrimeScript RT Master Mix (Takara, Japan) and 
used for qPCR analysis. Sequences of primers used 
for CD133 amplification are as follow: forward 5’- 
TGGATGCAGAACTTGACAACGT – 3’ and reverse 
5’-ATACCTGCTACGACAGTCGTGGT-3’. β-actin was 
amplified as an internal control. For each qPCR reaction, 
equal amounts of cDNA were mixed with Power SYBR 
Green PCR master mix (Applied Biosystems, Carlsbad, 
CA) and 5 pmol each of forward and reverse primers. 
miRCURY LNA miRNA assays were used to quantify 
the expression levels of mature miR-142-3p (Exiqon). 
Total RNA was reverse transcribed by the Universal 
cDNA Synthesis Kit II (Exiqon), while quantification 
of mature miRNAs was performed using the ExiLENT 
SYBR Green Master Mix (Exiqon). SNORD48 small 
nuclear RNA was amplified as an internal control. qPCR 
for both mRNA and miRNA detection was conducted at 
95°C for 10 min, followed by 40 cycles of 95°C for 15 
sec and 60°C for 1 min. Specificity was verified by melt 
curve analysis. The crossing threshold value was noted for 
each transcript and normalized to the internal control. The 
relative quantification of each mRNA and miRNA was 
performed using the comparative Ct method. Experiments 
were performed using an ABI Prism 7900 System and data 
were processed using ABI SDS v2.1 software (Applied 
Biosystems). 
Western blot
Quantified protein lysates were resolved on SDS-
PAGE, transferred onto PVDF membrane (Millipore, 
Billerica, MA) and probed with mouse anti-human 
CD133/1 (W6B3C1, Miltenyi Biotec) or mouse anti-
human actin (Santa Cruz, Dallas, TX), followed by 
incubation with secondary HRP-conjugated antibodies. 
Blots were visualized by chemiluminescence (Amersham, 
UK). 
Flow cytometry
Flow cytometry for CD133 expression was 
performed on liver cell lines using PE-conjugated 
monoclonal mouse anti-human CD133/1 (AC133, Miltenyi 
Biotec). Isotype control mouse IgG1-PE (eBioscience, San 
Diego, CA) served as a control. Samples were analyzed 
on a BD FACSCalibur (BD Biosciences, Franklin Lakes, 
NJ) and data were analyzed using CellQuest software (BD 
Biosciences).
miRNA-mRNA target prediction
To identify potential binding miRNA partners for 
CD133, a search in the publicly available alogrithims 
TargetScan (www.targetscan.org) Release 6.2 (June 2012) 
and miRanda (www.microrna.org) August 2010 Release 
was performed. 
Luciferase reporter assay
Full-length wild-type CD133 3’UTR was amplified 
and cloned into the MluI and HindIII sites of a firefly 
luciferase (f-luc) reporter gene of a pMIR-REPORT 
vector (Ambion, Carlsbad, CA) in sense or antisense 
directions. All PCR products cloned into the plasmid were 
verified by DNA sequencing to ensure that they were 
free of mutations and in the correct cloning direction. 
Sequence of primers used for luciferase reporter assays 
are provided in Supplementary Table 2. 293 cells were co-
transfected with 600 ng of either the sense or antisense 
firefly luciferase constructs, 0.1 μg of pRL-TK (Promega, 
Madison, WI) and 30 nM synthetic miR-142-3p molecules 
or mock control (Negative Control #1, non-targeting 
RNA oligonucleotide; Ambion). The pRL-TK Renilla 
luciferase plasmid was used as an internal control to 
correct for differences in both transfection and harvest 
efficiencies. Forty-eight hrs after transfection, firefly and 
Renilla luciferase activities were measured using the 
Dual-Luciferase Reporter Assay (Promega). Results were 
expressed as relative luciferase activity (firefly luciferase/
Renilla luciferase).
Lentiviral transduction and transfection
Lentiviral constructs (Lenti-miRTM microRNA 
precursor clones, System Biosciences, Mountain View, 
CA) expressing miR-142-3p or their respective empty 
vector (EV) controls (scramble control hairpin in pCDH-
CMV-MCS-EF1-copGFP, System Biosciences) were 
packaged using the pPACKH1 Lentivector Packaging 
System (System Biosciences) and were used to infect Huh7 
and PLC8024 HCC cells to establish cells constitutively 
expressing miR-142-3p. The transduction efficiency, as 
evaluated by GFP expression, was >90%. Stable clones 
were selected using puromycin. Cells were infected with 
lentiviral media at a multiplicity of infection of 10 in the 
presence of 8 mg/ml polybrene (Sigma-Aldrich) overnight 
in a 37oC incubator. For stable overexpression of CD133, 
negative control vector in pReceiver-M68 or CD133 in 
pReceiver-M68 (GeneCopoeia, Rockville, MD) was 
transfected into Huh7 cells using Lipofectamine 2000 
Reagent (Invitrogen) with stable clones selected using 
puromycin. 
Foci formation assay
Proliferation rates were determined by colorimetric 
assay using crystal violet (Sigma-Aldrich), a cytochemical 
stain that binds to chromatin.
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Spheroid formation assay
Single cells were cultured in 300 µl of serum-
free DMEM/F12 medium (Invitrogen) supplemented 
with 20 ng/ml human recombinant epidermal growth 
factor (Sigma-Aldrich), 10 ng/ml human recombinant 
basic fibroblast growth factor (Invitrogen), 4 µg/ml 
insulin (Sigma-Aldrich), B27 (1:50; Invitrogen), 500 U/
ml penicillin (Invitrogen) and 500 µg/ml streptomycin 
(Invitrogen). Cells were cultured in suspension in poly-
HEMA-coated 24-well plates. Cells were replenished 
with 30 µl of supplemented medium every second day. 
To propagate spheres in vitro, spheres were collected by 
gentle centrifugation and dissociated to single cells using 
TrypLE Express (Invitrogen). Following dissociation, 
trypsin inhibitor (Invitrogen) was used to neutralize the 
reaction, and the cells were cultured to generate the next 
generation of spheres.
Chemoresistance assay
Cells were treated with various concentrations of 
5-fluorouracil (5-FU) and cisplatin (Huh7 with 250 µg/
mL 5-FU or 10 µg/mL cisplatin and PLC8024 with 250 
µg/mL 5-FU or 5 µg/mL cisplatin) for 48 hrs; and then 
harvested and stained in binding buffer, 7-AAD and APC-
conjugated Annexin-V as provided by the Annexin-V APC 
Apoptosis Detection Kit (BD Biosciences) according to 
manufacturer’s instructions. Analysis was determined by 
FACSCanto II and FACSDiva software (BD Biosciences).
Cell invasion and motility assay
Invasion and migration assays were conducted 
in 24-well BioCoat Matrigel Invasion Chambers (BD 
Biosciences) or 24-well Millicell hanging inserts 
(Millipore). Cells re-suspended in serum free DMEM 
were added to the top chamber and DMEM supplemented 
with 10% FBS was added to the bottom chamber as 
a chemoattractant. After 48 hrs incubation at 37°C, 
the number of cells that invaded through the Matrigel 
(invasion) or membrane (migration) was counted in 10 
fields under 4x objective lens and imaged using SPOT 
imaging software (Nikon, Japan).
Capillary tube formation assay
Huh7 and PLC8024 cells infected with miR-142-3p 
or empty vector controls were plated into 6-well plates in 
DMEM medium containing 10% FBS. Culture medium 
was replaced by fresh medium without FBS after 24 
hrs. Cell supernatants were collected and filtered after 
incubation for a further 24 hrs. HUVECs (1x104) were 
seeded into 96-well plates and then treated with the tumor 
cell supernatant for 48 hrs. Capillary tube formation 
assays were then conducted using BD Matrigel Basement 
Membrane Matrix (BD Biosciences), according to the 
manufacturer’s instructions.
Animal experimentations
The study protocol was approved by and performed 
in accordance with the Committee of the Use of Live 
Animals in Teaching and Research at The University 
of Hong Kong. Tumorigenicity was determined by 
subcutaneous injection into the flank of 4-to-5 week old 
nude mice. Specifically, HCC cells infected with miR-142-
3p or empty vector controls were injected subcutaneously 
in complete medium. Each group contained five animals. 
Cryosections (5 µm thick) were stained with hematoxylin 
and eosin stain. Animals that were injected with tumor 
cells but showed no sign of tumor burden were generally 
terminated three months after tumor cell inoculation, and 
animals were opened up at the injection sites to confirm 
that there was no tumor development. 
Statistical analyses
All statistical analyses were performed using 
PASW Statistics 18.0 (SPSS Inc., Chicago, IL), with the 
exception of the significance in bar graphs, in which case 
analyses were performed by applying the independent 
t-test using Microsoft Office Excel software (Microsoft 
Corp., Redmond, WA). A p-value of less than 0.05 was 
considered significant. miR-142-3p levels in HCC and 
adjacent non-tumor tissues were compared by paired 
Student t test. Differences in miR-142-3p expression 
among various clinicopathological stages were analyzed 
by Pearson chi-square (χ2) test or Fisher’s Exact test, 
where appropriate. Cases with ΔCt lower than the 
mean value were classified as having high miR-142-
3p expression, while cases with ΔCt higher than the 
mean value were classified as having low miR-142-3p 
expression. The Kaplan-Meier method and the log-rank 
test were used to compare the survival, defined as the time 
from surgery until death (living patients were censored at 
the time of their last follow up).
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